

AMENDMENTS TO THE SEQUENCE LISTING

Please replace the paper copy of the Sequence Listing with the attached substitute paper copy of the Sequence Listing. Please replace the computer readable form of the Sequence Listing with the attached substitute copy of the computer readable form of the Sequence Listing.

In the substitute paper copy and the substitute computer readable form of the Sequence Listing, new SEQ ID NOs:24-28 have been added. SEQ ID NOs:24-28 depict hKv1.5LOOP (and hKv1.6LOOP), hKv3.4LOOP, hKv β 1bN (and hKv β 3N), hKv3.4N, and hKv β 1CN, respectively. These sequences are supported at least by Figures 1 and 2 of the present application.

Attachment: substitute paper copy of the Sequence Listing
 substitute computer readable form of the Sequence Listing

REMARKS

Claims 59-62 are pending and have been allowed. Applicants are thankful to the Examiner for the allowance of these claims.


In the Office Action, the Examiner requests Applicants to provide sequence identifiers for the sequences depicted in Figures 1 and 2. Applicants have amended the specification to recite in the Brief Description of the Figures that the “intracellular receptor regions of hKv1.1, hKv1.2, hKv1.3, hKv1.4, hKv1.5, hKv1.6, and hKv3.4 are designated as hKv1.1LOOP (SEQ ID NO:1), hKv1.2LOOP (SEQ ID NO:1), hKv1.3LOOP (SEQ ID NO:1), hKv1.4LOOP (SEQ ID NO:2), hKv1.5LOOP (SEQ ID NO:24), hKv1.6LOOP (SEQ ID NO:24), and hKv3.4LOOP (SEQ ID NO:25), respectively” and that the “amino-terminal inactivation regions of hKv β 1, hKv β 1b, hKv β 3, hKv3.4, hKv β 1c, and hKv1.4 are designated as hKv β 1N (SEQ ID NO:5), hKv β 1bN (SEQ ID NO:26), hKv β 3N (SEQ ID NO:26), hKv3.4N (SEQ ID NO:27), hKv β 1CN (SEQ ID NO:28), and hKv1.4N (SEQ ID NO:6), respectively.” Applicants respectfully submit that this amendment addresses the Examiner’s concern.

Applicants have also amended the paper copy and the computer readable form of the Sequence Listing by adding new SEQ ID NOs: 24-28. SEQ ID NOs: 24-28 depict hKv1.5LOOP (and hKv1.6LOOP), hKv3.4LOOP, hKv β 1bN (and hKv β 3N), hKv3.4N, and hKv β 1CN, respectively. These sequences are supported at least by Figures 1 and 2 of the present application. In addition, Applicants have changed the sources for SEQ ID NOs: 3-4, 7-8, and 9-23. These changes are supported at least by page 8, lines 23-25 and 30-33; and from page 28, line 3, to page 35, line 26, of the specification. A substitute paper copy and a substitute computer readable form of the Sequence Listing are also provided, incorporating the aforementioned changes.

Applicants respectfully submit that the amendments to the specification and the Sequence Listing do not introduce new matter. Entry of these amendments is, therefore, respectfully requested.

Although Applicants believe that no fee is due for the instant reply, the Commissioner is hereby authorized to charge any payment deficiency to deposit account number 19-2380 referring to attorney docket number 031896-069100. Should the Examiner have any questions, the Examiner is invited to contact Applicants’ undersigned representative at the telephone number listed below.

Respectfully submitted,


Raymond Van Dyke
Reg. No. 34,746

Date: July 28, 2005

Nixon Peabody LLP
401 9th Street, N.W.
Washington, D.C. 20004-2128
Tel: (202) 585-8250
Fax: (202) 585-8080